Compare New York Times Co (NYT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Recursion Pharmaceuticals Inc — how do they compare? New York Times Co trades at $65.57 (market cap $10.74B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: New York Times Co is far larger — about 5× Recursion Pharmaceuticals Inc's market cap, and New York Times Co pays a 1.38% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NYT | RXRX | |
|---|---|---|
Market Cap | $10.74B | $2.14B |
Volume | 2,096,352 | 30,789,535 |
Sector | Media | Health |
52-Week High | $85.86 | $6.79 |
52-Week Low | $54.66 | $2.84 |
Typical Hold Time | 81 Days | 22 Days |
Enterprise Value | $10.14B | $1.66B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $64.90, up 1.3% with a bearish technical signal despite strong fundamental performance. Recent earnings beats and consistent revenue growth to $2.82 billion in 2025 highlight operational strength, though a shareholder lawsuit and AI copyright disputes present headwinds. Analyst consensus is mixed with a $84 price target suggesting 29% upside from current levels.
The stock offers value through earnings growth and dividend yield, but faces sentiment pressure from legal challenges and technical indicators. Key risks include litigation outcomes and competitive pressures in digital media, while institutional ownership trends and positive cash flow generation support the investment case for patient investors.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
